Anti-staphylococcal potential of Callistemon rigidus

• Authors: Charu Gomber , Sanjai Saxena
• Languages of publication: EN

Abstracts

EN

The last decade witnessed the emergence of Staphylococcus aureus- a versatile human pathogen, as a deadly superbug. The enormous genetic plasticity of the organism assists it to endlessly evolve resistance mechanisms against existing anti-infectives thus necessitating the need to control the spread of resistant staphylococcal isolates in hospitals and health care settings. This in turn demands the incessant exploration of newer biological matrices in search of diverse chemical entities with novel drug targets. Since time immemorial higher plants continue to be the best source of newer compounds with high therapeutic potential. Lead fractions from same or different plants can be developed into effective antibacterial polyherbal formulations. A lead fraction from methanolic extract of leaves of Callistemon rigidus exhibited a dose dependent antistaphylococcal activity during in vitro agar well assay against a panel of twenty seven clinical multidrug resistant S. aureus isolates. Further, minimal inhibitory concentration (MIC) evaluation by in vitro 96-well microplate based assay established a MIC range of 1.25–80 μg/ml as compared to 5–320 μg/ml of positive control, Cefuroxime sodium. The MIC50 and MIC90 of the methanolic lead fraction were 5 μg/ml and 40 μg/ml respectively. The present study thus signifies the vast potential of the lead fraction from Callistemon rigidus for future development into a herbal drug/ formulation and to impede global health crisis due to multidrug resistant Staphylococcus aureus.

Keywords

EN

Antibacterial activity; multidrug resistance; Staphylococcus aureus; Callistemon rigidus; minimal inhibitory concentration

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2007
• Volume: 2
• Issue: 1
• Pages: 79-88

Dates

published

1 - 3 - 2007

online

1 - 3 - 2007

Contributors

author

Charu Gomber

• Department of Biotechnology & Environmental Sciences, Thapar Institute of Engineering & Technology, Deemed University, Patiala, Punjab, 147004, India

author

Sanjai Saxena

• Department of Biotechnology & Environmental Sciences, Thapar Institute of Engineering & Technology, Deemed University, Patiala, Punjab, 147004, India

References

• [1] G.J. Moran, R.N. Amii, F.M. Abrahamian and D.A. Talan: “Methicillin resistant Staphylococcus aureus in community-acquired skin infections”, Emerg. Infec. Dis., Vol. 11, (2005), pp. 928–930. [Crossref]
• [2] Y. Yamazaki, K. Hirai and T. Honda: “Pseudomembranous tracheobronchitis caused by Methicillin resistant Staphylococcus aureus”, Scand. J. Infect. Dis., Vol. 34, (2001), pp. 211–221. http://dx.doi.org/10.1080/00365540110077083[Crossref]
• [3] H. Watanabe, L. Masaki, N. Asoh, K. Watanabe, K. Oishi, S. Kobayashi, A. Sato and T. Nagataka: “Molecular analysis of Methicillin resistant Staphylococcus aureus as a causative agent of Bronchopulmonary infection: relation to colonization in upper respiratory tract”, J. Clin. Microbiol., Vol. 38, (2000), pp. 3867–3869.
• [4] V.G. Fowler, M.K. Olsen, G.R. Corey, C.W. Woods, C.H. Cabell, H.B. Reller: “Clinical identifiers of complicated Staphylococcus aureus bacteraemia”, Arch. Intern. Med., Vol. 163, (2003), 2066–2072. http://dx.doi.org/10.1001/archinte.163.17.2066[Crossref]
• [5] F. Vandenesch, N. Timothy, M. Enright, G. Lina, G.R. Nimmo, H. Heffernan, N. Liassine, M. Bes, T. Greenland, M.E. Reverdy and J. Etienne: “Community acquired Methicillin resistance Staphylococcus aureus carrying Panton-Valentine Leukocidin genes: worldwide emergence”, Emerg. Infect. Diseases., Vol. 9, (2003), pp. 978–984. [Crossref]
• [6] F.J. Schmitz, A.D.C. Fluit, M. Gandolf, R. Beyrau, E. Lindenlauf, J. Verhoef and M.E. Jones: “The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of Staphylococci from 19 European hospitals”, J. Antimicrob. Chemother., Vol. 43, (1999), pp. 253–259. http://dx.doi.org/10.1093/jac/43.2.253[Crossref]
• [7] Alghaithy AA, N.E. Bilal, M. Gedebou and A.H. Wiley: “Nasal carriage and antibiotic Staphylococcus aureus isolates from hospital and non-hospital personnel in Abha, Saudi, Arabia. Trans. R. Soc. Trop. Med. Hyg., Vol. 94, (2000), pp. 504–507. http://dx.doi.org/10.1016/S0035-9203(00)90066-X[Crossref]
• [8] T. Kluytmann, A.V. Belkum and H. Verbrugh: “Nasal carriage of Staphylococcus aureus: epidemiology, mechanisms and associated risks”, Clin. Microbiol. Rev., Vol. 10, (1997), pp. 505–520.
• [9] H.K. Tiwari and M.R. Sen: “Emergence of vancomycin resistant Staphylococcus aureus from a tertiary care hospital from northern part of India”, BMC Infec. Dis., Vol. 6, (2006), pp. 156–161. http://dx.doi.org/10.1186/1471-2334-6-156[Crossref]
• [10] S.E. Cosgrove, K.C. Carroll and T.M. Perl: “Staphylococcus aureus with reduced susceptibility to vancomycin”, Clin. Infec. Dis., Vol. 39, (2004), pp. 539–545. http://dx.doi.org/10.1086/422458[Crossref]
• [11] K. Hiramatsu, N. Aritaka and H. Hanaki: “Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin”, Lancet, Vol. 350, (1997), pp. 1668–1671. http://dx.doi.org/10.1016/S0140-6736(97)07324-8[Crossref]
• [12] S. Saxena and D. Kumar: “Tailoring biodiversity for the development of new therapeutics”, Nat. Prod. Rad., Vol. 1, (2002), pp. 18–25.
• [13] E. Bombardelli: “Approaches to the quality characteristics of medicinal plant derivatives”, Eur. Phytojournal, Vol. 1, (2001), pp. 30–33.
• [14] L. Jirovetz, W. Fleischhacker, G. Buchbauer and M.B. Ngassoum: “Analysis of the essential oils of Callistemon rigidus (Myrtaceae) from Cameroon by GC/FID and GC/MS”, Sci. Pharm., Vol. 65, (1997), pp. 315–319.
• [15] S. Saxena and C. Gomber: “Antimicrobial potential of Callistemon rigidus”, Pharm. Biol., Vol. 44, (2006), pp. 194–201. [Crossref]
• [16] National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disc Susceptibility tests, NCCLS M100-S12, (2002).
• [17] C. Perez, M. Paul and P. Bazerque: “Antibiotic assay by agar well diffusion”, Pharm. Biol. Vol. 43, (1990), pp. 67–71.
• [18] Eucast definitive Document E.Def.3.1. European Committee for Antimicrobial Susceptibility Testing: “Determination of minimum inhibitory concentrations (MIC’s) of antibacterial agents by agar dilution”, Clin. Microbiol. & Infec., Vol. 6, (2000), pp. 509–515. http://dx.doi.org/10.1046/j.1469-0691.2000.00142.x[Crossref]
• [19] J.M. Andrews: “Determination of minimum inhibitory concentrations”, J. Antimicrob. Chemother., Vol. 48(S1), pp. 5–16.
• [20] K. Guven, S. Celik and I. Uysal: “Antimicrobial Activity of Centaurea Species”, Pharm. Biol. Vol. 43, (2005), pp. 67–71. [Crossref]
• [21] C.V. Nakamura, N.T. Ueda, E. Bando, A.F.N. Melo, D.A.G. Cortez and B.P.D. Filho: “Antibacterial activity of Ocimum gratissimum L. essential oil”, Mem. Inst. Oswaldo Cruz, Vol. 94, (1999), pp. 675–678.
• [22] I.K. Sawer, M.I. Berry and J.L. Ford: “The killing effect of cryptolepine on Staphylococcus aureus”, Lett. Appl. Microbiol., Vol. 40, (2005), pp. 24–29. http://dx.doi.org/10.1111/j.1472-765X.2004.01625.x[Crossref]
• [23] M. Canales-Martinez, T. Hernandez-Delgado, C. Flores-Ortiz, A. Duran-Dyaz, A.M. Garcya-Bores and G. Avila-Acevedo: “Antimicrobial Activity of Alternanthera caracasana”, Pharm. Biol., Vol. 43, (2005), pp. 305–307. http://dx.doi.org/10.1080/13880200590951685[Crossref]
• [24] C.U. Iroegbu and C.K. Nkere: “Evaluation of the antibacterial properties of Picralima nitida stembark extracts”, Int. J. Mol. Med. Adv. Sci., Vol. 1(2), pp 182–189.
• [25] P.S. Negi and G.K. Jayaprakasha: “Antibacterial activity of grapefruit (Citrus paradisi) peel extracts”, Eur. Food Res. Tech., Vol. 213, (2001), pp. 481–487.
• [26] S.V. Reddy, P.V. Srinivas, B. Praveen, K.H. Kishore, B.C. Raju, U.S. Murthy and J.M. Rao: “Antibacterial constituents from the berries of Piper nigrum”, Phytomed., Vol. 11, (2004), pp. 697–700. http://dx.doi.org/10.1016/j.phymed.2003.04.004[Crossref]
• [27] U. Ajali and B.K.C. Chukwurah: “Antimicrobial activity of Securidaca longipenduculata”, Phytomed., Vol. 11, (2004), pp. 701–703. http://dx.doi.org/10.1016/j.phymed.2003.07.002[Crossref]
• [28] S. Mansouri, A. Foroumadi, T. Ghaneie and A.G. Najar: “Antibacterial activity of crude extracts and fractionated constituents of Myrtus communis”, Pharm. Biol., Vol. 39, (2001), pp. 399–401. [Crossref]
• [29] C.D. Djipa, M. Delmee and J.Q. Leclarcq: “Antimicrobial activity of bark extracts of Piper, Syzygium jambos (L.), Alston (Myrtaceae)”, J. Ethnopharmacol., Vol. 71, (2001), pp. 303–307.

Identifiers

DOI

10.2478/s11536-007-0004-8